Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Potentiation of calcitonin by corticosteroids during the treatment of the hypercalcaemia of malignancy.

Literature DB >> 2328745

Potentiation of calcitonin by corticosteroids during the treatment of the hypercalcaemia of malignancy.

D J Hosking¹, M D Stone, J W Foote.
1. City Hospital, Nottingham.

Abstract

Some patients treated for the hypercalcaemia of malignancy develop renal tubular resistance to the effects of calcitonin which is independent of concurrent changes in sodium excretion. This type of resistance can be overcome by the addition of corticosteroids. In other patients apparent renal resistance to calcitonin is a consequence of reduced sodium excretion and is unaffected by corticosteroids.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1990 PMID： 2328745 DOI： 10.1007/bf00314800

Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN： 0031-6970 Impact factor: 2.953

20 in total

1. Calcitonin treatment of hypercalcemia due to parathyroid carcinoma. Synergistic effect of prednisone on long-term treatment of hypercalcemia.

Authors: W Y Au
Journal: Arch Intern Med Date: 1975-12

Review 2. Calcitonin binding sites in bone: relationships to biological response and "escape".

Authors: A H Tashjian; D R Wright; J L Ivey; A Pont
Journal: Recent Prog Horm Res Date: 1978

Review 3. Renal tubular transport of calcium: update.

Authors: Z S Agus
Journal: Adv Exp Med Biol Date: 1978 Impact factor: 2.622

4. Salmon calcitonin in the treatment of hypercalcemia.

Authors: O L Silva; K L Becker
Journal: Arch Intern Med Date: 1973-09

5. Acute effects of saline, calcitonin, and hydrocortisone on plasma calcium in vitamin D intoxication.

Authors: P J Heyburn; R M Francis; M Peacock
Journal: Br Med J Date: 1979-01-27

6. Rehydration in the treatment of severe hypercalcaemia.

Authors: D J Hosking; A Cowley; C A Bucknall
Journal: Q J Med Date: 1981

7. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.

Authors: S H Ralston; M D Gardner; F J Dryburgh; A S Jenkins; R A Cowan; I T Boyle
Journal: Lancet Date: 1985-10-26 Impact factor: 79.321

8. Effect of calcitonin and glutocorticoids in combination on the hypercalcemia of malignancy.

Authors: M L Binstock; G R Mundy
Journal: Ann Intern Med Date: 1980-08 Impact factor: 25.391

Review 9. Calcium transport in the nephron.

Authors: W N Suki
Journal: Am J Physiol Date: 1979-07

10. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors: F J van Breukelen; O L Bijvoet; A T van Oosterom
Journal: Lancet Date: 1979-04-14 Impact factor: 79.321

3 in total

Review 1. Hypercalcemia of malignancy.

Authors: V Grill; T J Martin
Journal: Rev Endocr Metab Disord Date: 2000-11 Impact factor: 6.514

Review 2. Assessment of renal and skeletal components of hypercalcemia.

Authors: D J Hosking
Journal: Calcif Tissue Int Date: 1990 Impact factor: 4.333

Review 3. Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors: S Patel; A R Lyons; D J Hosking
Journal: Drugs Date: 1993-10 Impact factor: 9.546

3 in total